Scientists have discovered a direct link between gut immune responses and brain inflammation in multiple sclerosis (MS), revealing that intestinal cells can activate harmful immune cells that then migrate to the brain and spinal cord. This breakthrough, published in Science Immunology in March 2026, explains how the gut shapes autoimmune neurological disease and suggests new therapeutic targets beyond current MS treatments .

How Does the Gut Trigger Brain Inflammation in MS?

Multiple sclerosis occurs when the immune system mistakenly attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. For years, researchers knew that gut bacteria and the gut microbiota play a role in MS development, but the exact mechanism remained a mystery. A team led by Dr. Shohei Suzuki and Dr. Tomohisa Sujino at Keio University in Japan set out to identify how gut immune responses contribute to brain inflammation .

The researchers made a surprising discovery: intestinal epithelial cells (IECs), which line the gut wall, can directly present antigens to immune cells in a way that triggers the formation of harmful Th17 cells. Th17 cells are a type of CD4+ T cell that drives pro-inflammatory responses. In both mouse models of MS and in actual MS patients, these inflammatory Th17 cells accumulated in the intestine, suggesting a conserved gut-to-brain pathway active in human disease .

The key finding involved a molecule called MHC class II (major histocompatibility complex class II), which intestinal epithelial cells upregulated in both diseased mice and MS patients. When researchers selectively deleted MHC II from intestinal epithelial cells in mice, pathogenic Th17 cell generation decreased and disease severity improved. This demonstrated that MHC II expression on gut cells is essential for activating the harmful T cells that drive MS .

What Happens After T Cells Activate in the Gut?

Once activated in the gut, these pathogenic Th17 cells don't stay put. Using advanced tracking technology with transgenic mice expressing a fluorescent protein called Kaede, researchers traced the journey of Th17 cells from the intestinal lamina propria (the tissue layer beneath the gut lining) directly to the spinal cord, where they drive neuroinflammation. This elegant experiment provided visual proof that gut-activated T cells migrate to the central nervous system and cause brain and spinal cord inflammation .

"Increasing evidence shows that the gut microbiota influences neurological diseases such as Parkinson's, Alzheimer's, and MS. However, the mechanisms linking gut microbes, intestinal immunity, and brain inflammation remain unclear. We were keen to identify how gut immune responses contribute to neuroinflammatory diseases," explained Dr. Tomohisa Sujino, Associate Professor at Keio University's School of Medicine.

Dr. Tomohisa Sujino, Associate Professor, School of Medicine, Keio University

Ways to Leverage This Discovery for Better MS Treatment

• Modulate Intestinal Microbiota: Altering the composition of gut bacteria through dietary changes, probiotics, or targeted antimicrobial approaches could reduce the activation of pathogenic Th17 cells before they ever reach the brain.
• Target Antigen-Presenting Activity: Blocking or reducing MHC II expression on intestinal epithelial cells could prevent the initial activation of harmful T cells in the gut, stopping the cascade before it begins.
• Shift Focus from B Cells to Gut Immunity: Current MS therapies primarily target B cells in the bloodstream, but this discovery suggests that modulating gut immune responses represents a fundamentally different therapeutic approach that could complement or enhance existing treatments.

The implications are significant because current MS therapies have limitations. Most approved treatments focus on B cells, a different type of immune cell that circulates in the blood. By identifying the gut as a critical site where pathogenic T cells are first activated, researchers have opened an entirely new therapeutic avenue .

"While current therapies for MS often target B cells, our study highlights the gut as an important therapeutic site. Modulating intestinal microbiota or antigen-presenting activity of IECs represents new approaches to treating autoimmune neurological diseases," stated Dr. Shohei Suzuki, Assistant Professor in the Division of Gastroenterology and Hepatology at Keio University.

Dr. Shohei Suzuki, Assistant Professor, Division of Gastroenterology and Hepatology, Keio University

Why Does This Gut-Brain Connection Matter for MS Patients?

This discovery reframes how scientists think about MS as a disease. Rather than viewing it solely as a brain disorder, this research demonstrates that MS is fundamentally a disease of the gut-brain axis, where events in the intestine directly shape immune responses in the central nervous system. MS patients already show alterations in their gut microbiota compared to healthy individuals, and this study explains why those changes matter .

The finding also explains why environmental factors and lifestyle choices that affect gut health, such as diet and microbial exposure, influence MS risk and progression. It suggests that interventions targeting the gut could potentially slow disease progression or prevent MS from developing in genetically susceptible individuals. This is particularly important because MS affects approximately 2.3 million people worldwide, and current treatments, while helpful, don't work equally well for everyone and can have significant side effects .

The research team's work demonstrates that while systemic circulation allows T cells to exchange between immune tissues throughout the body, the epithelial-immune interactions within the gut mucosal compartment can essentially shape effector T cell responses in the brain. This represents a paradigm shift in understanding autoimmune neurological diseases and opens the door to developing therapies that target the gut as a primary site of intervention rather than treating only the downstream effects in the brain .